FDA approves Scholar Rock therapy for rare muscle-weakness disorder
The U.S. Food and Drug Administration approved a Scholar Rock therapy for a rare genetic condition that causes muscle weakness. The supplied report does not specify the therapy’s product name, approval label, or commercial terms.
The Reuters wire explicitly reports that the U.S. FDA approved a Scholar Rock therapy for a rare genetic condition causing muscle weakness, which is a new and materially forward-looking regulatory milestone for SRRK. The direct report does not identify the product name, approval label, or commercial terms, so the finalized name and description remain generic rather than asserting details inferred from surrounding apitegromab materials. Other supplied records still describe the related therapy as pending FDA review, which creates some evidentiary conflict and warrants a modest reduction from the initial confidence score; the direct approval report is treated as the latest development-specific evidence. The approval date is supported as September 11, 2026, but the exact time is not provided, so 00:00 UTC is used as a date-level estimate.
The U.S. Food and Drug Administration on Friday approved Scholar Rock's NASDAQ:SRRK therapy to treat a rare genetic condition that causes muscle weakness.